Table 2.
Epidemiological and clinical features
| Case group (underlying diseases) | Previously healthy group | P value | |
|---|---|---|---|
| Median age (IQR Q1-Q3) (months) | 12·49 (5·26–23·21) | 2·96 (1·32–6·80) | <0·001 |
| Prematurity (≤37 weeks) | 67/155 (43·2%) | 63/386 (16·3%) | <0·001 |
| Palivizumab (previous administration) | 30/179 (16·7%) | 8/425 (1·8%) | <0·001 |
| Duration of fever (mean) (days) | 2·89 | 2·24 | <0·001 |
| Poor feeding | 38/225 (16·9%) | 81/460 (17%) | n.s. |
| Respiratory distress | 182/225 (80·9%) | 354/460 (77·0%) | n.s. |
| Hypoxemia at admission (O2 Sat <92%) | 114/225 (50·7%) | 151/460 (32·8%) | <0·001 |
| Chest X-ray | 172/225 (76·4%) | 243/460 (52·8%) | <0·001 |
| Pathologic chest X-ray | 137/172 (79·6%) | 190/243 (78·2%) | n.s. |
IQR, interquartile range; Q1, quartile 1; Q3, quartile 3; n.s., non-significant.